InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Axsome Therapeutics, Inc.

AXSM Clue Score54
United States Fiscal year ends December CIK 0001579428
$168.35 -1.02% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $168.35 +416.09% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Operating income−27.5Net income−27.2Fiscal year 2017Operating income−27.2Net income−28.9Fiscal year 2018Operating income−32.8Net income−31.0Fiscal year 2019Operating income−67.2Net income−68.3Fiscal year 2020Operating income−99.1Net income−102.9EPS, diluted−2.77Fiscal year 2021Operating income−124.7Net income−130.4EPS, diluted−3.47Fiscal year 2022Revenue50.0Operating income−179.8Net income−187.1EPS, diluted−4.60Fiscal year 2023Revenue270.6 +440.8%Operating income−231.8Net income−239.2EPS, diluted−5.27Fiscal year 2024Revenue385.7 +42.5%Operating income−280.6Net income−287.2EPS, diluted−5.99Fiscal year 2025Revenue638.5 +65.5%Operating income−166.8Net income−183.2EPS, diluted−3.68
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a n/a n/a 50.0 270.6 385.7 638.5
Growth +440.8% +42.5% +65.5%
Operating income −27.5 −27.2 −32.8 −67.2 −99.1 −124.7 −179.8 −231.8 −280.6 −166.8
Net income −27.2 −28.9 −31.0 −68.3 −102.9 −130.4 −187.1 −239.2 −287.2 −183.2
Growth
EPS, diluted n/a n/a n/a n/a −2.77 −3.47 −4.60 −5.27 −5.99 −3.68
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2016Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Operating margin−359.3%Net margin−374.0%Free cash flow margin−234.3%Fiscal year 2023Operating margin−85.7%Net margin−88.4%Free cash flow margin−53.8%Fiscal year 2024Operating margin−72.7%Net margin−74.5%Free cash flow margin−33.4%Fiscal year 2025Operating margin−26.1%Net margin−28.7%Free cash flow margin−14.7%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a n/a n/a −359.3% −85.7% −72.7% −26.1%
Net margin n/a n/a n/a n/a n/a n/a −374.0% −88.4% −74.5% −28.7%
Free cash flow margin n/a n/a n/a n/a n/a n/a −234.3% −53.8% −33.4% −14.7%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−21.3Capital expenditure−0.1Free cash flow−21.4Fiscal year 2017Operating cash flow−26.5Capital expenditure−0.0Free cash flow−26.5Fiscal year 2018Operating cash flow−30.1Capital expenditure−0.0Free cash flow−30.1Fiscal year 2019Operating cash flow−46.4Capital expenditure−0.0Free cash flow−46.4Fiscal year 2020Operating cash flow−78.5Capital expenditure−0.0Free cash flow−78.5Fiscal year 2021Operating cash flow−108.2Capital expenditure−0.3Free cash flow−108.5Fiscal year 2022Operating cash flow−116.5Capital expenditure−0.7Free cash flow−117.2Fiscal year 2023Operating cash flow−145.1Capital expenditure−0.6Free cash flow−145.7Fiscal year 2024Operating cash flow−128.4Capital expenditure−0.3Free cash flow−128.7Fiscal year 2025Operating cash flow−93.4Capital expenditure−0.5Free cash flow−93.9
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −21.3 −26.5 −30.1 −46.4 −78.5 −108.2 −116.5 −145.1 −128.4 −93.4
Capital expenditure −0.1 −0.0 −0.0 −0.0 −0.0 −0.3 −0.7 −0.6 −0.3 −0.5
Free cash flow −21.4 −26.5 −30.1 −46.4 −78.5 −108.5 −117.2 −145.7 −128.7 −93.9
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2016Total debt9.7Shareholders’ equity21.6Debt to equity0.45Fiscal year 2017Total debt9.9Shareholders’ equity16.7Debt to equity0.59Fiscal year 2018Total debt6.9Shareholders’ equity0.9Debt to equity7.37Fiscal year 2019Cash220.0Total debt19.9Net cash (debt)200.0Shareholders’ equity178.7Debt to equity0.11Fiscal year 2020Cash183.9Total debt48.3Net cash (debt)135.6Shareholders’ equity113.8Debt to equity0.42Fiscal year 2021Cash86.5Total debt49.1Net cash (debt)37.4Shareholders’ equity15.6Debt to equity3.14Fiscal year 2022Cash200.8Total debt94.3Net cash (debt)106.6Shareholders’ equity109.6Debt to equity0.86Fiscal year 2023Cash386.2Total debt178.1Net cash (debt)208.1Shareholders’ equity191.0Debt to equity0.93Fiscal year 2024Cash315.4Total debt180.7Net cash (debt)134.6Shareholders’ equity57.0Debt to equity3.17Fiscal year 2025Cash322.9Total debt187.7Net cash (debt)135.2Shareholders’ equity88.3Debt to equity2.13
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash n/a n/a n/a 220.0 183.9 86.5 200.8 386.2 315.4 322.9
Total debt 9.7 9.9 6.9 19.9 48.3 49.1 94.3 178.1 180.7 187.7
Net cash (debt) n/a n/a n/a 200.0 135.6 37.4 106.6 208.1 134.6 135.2
Shareholders’ equity 21.6 16.7 0.9 178.7 113.8 15.6 109.6 191.0 57.0 88.3
Debt to equity 0.45 0.59 7.37 0.11 0.42 3.14 0.86 0.93 3.17 2.13

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−21.3 −26.5 −30.1 −46.4 −78.5 −108.2 −116.5 −145.1 −128.4 −93.4
Growth
Investment
−0.1 −0.0 −0.0 −0.0 −0.0 −0.3 −0.7 −0.6 −0.3 −0.5
calc −21.4 −26.5 −30.1 −46.4 −78.5 −108.5 −117.2 −145.7 −128.7 −93.9
Growth
calc n/a n/a n/a n/a −2.11 −2.89 −2.88 −3.21 −2.69 −1.89
−0.1 −0.0 −0.0 −0.0 −0.0 −0.3 −53.7 −0.6 −0.3 −0.5
Financing
10.0 23.9 10.0 252.4 42.4 11.1 284.6 331.0 57.8 101.5

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.